Antidepressant Drug Interactions and the Cytochrome P450 System: A Critical Appraisal

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

Volumn 15, Issue 6P2, 1995, Pages 84S-99S

  Riesenman, Cara ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; ASTEMIZOLE; BENZODIAZEPINE DERIVATIVE; CLONAZEPAM; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE; DESIPRAMINE; ENZYME INHIBITOR; ERYTHROMYCIN; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; ITRACONAZOLE; KETOCONAZOLE; MIDAZOLAM; NEFAZODONE; NORFLUOXETINE; NORSERTRALINE; PAROXETINE; PROPRANOLOL; QUINIDINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SPARTEINE; TERFENADINE; TRIAZOLAM; UNINDEXED DRUG; VENLAFAXINE;

AREA UNDER THE CURVE; CLINICAL TRIAL; CONFERENCE PAPER; DEPRESSION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; ENZYME INHIBITION; ENZYME SUBSTRATE; HUMAN; ORAL DRUG ADMINISTRATION;

1-NAPHTHYLAMINE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FLUOXETINE; FLUVOXAMINE; HUMAN; MIXED FUNCTION OXYGENASES; OXIDOREDUCTASES; PAROXETINE; SERTRALINE; STEROID HYDROXYLASES;

EID: 0028818646     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/j.1875-9114.1995.tb02909.x     Document Type: Article

References (79)

1. Recent developments in hepatic drug oxidation: implications for clinical pharmacokinetics
2. The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature
3. Extrahepatic metabolism of drugs in humans
4. Recent advances: the cytochrome P450 enzymes
5. The human hepatic cytochromes P450 involved in drug metabolism
6. Inhibition by paroxetine of desipramine metabolism in extensive but not poor metabolizers of sparteine
7. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S‐mephenytoin
8. Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects
9. Polymorphic debrisoquin hydroxylation in 757 Swedish subjects
10. Involvement of CYP2D6, CYP3A4, and other cytochrome P‐450 isozymes in n‐dealkylation reactions
11. Polymorphic dextromethorphan metabolism: co‐segregation of oxidative o‐demethylation with debrisoquin hydroxylation
12. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4
13. Major pathway of imipramine metabolism is catalyzed by cytochromes P‐450 1A2 and P‐450 3A4 in human liver
14. The mephenytoin oxidation polymorphism is partially responsible for the N‐demethylation of imipramine
15. A predictive model for substrates of cytochrome P450‐debrisoquine (2D6)
16. Inhibition of desipramine hydroxylation in vitro by serotonin‐reuptake‐inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo
17. In vitro prediction of the terfenadine‐ketoconazole pharmacokinetic interaction
18. Oxidation of quinidine by human liver cytochrome P‐450
19. Comparative inhibition of the polymorphic enzyme CYP2D6 by venlafaxine (VF) and other 5HT uptake inhibitors [abstr]
20. The effect of selective serotonin re‐uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes
21. Defective oxidation of drugs: pharmacokinetic and therapeutic implications
22. CYP2D6‐ and CYP3A‐dependent metabolism of dextromethorphan in humans
23. Are poor metabolisers of sparteine/debrisoquin less pain tolerant than extensive metabolisers
24. The relationship between paroxetine and the sparteine oxidation polymorphism
25. Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline
26. Influence of fluoxetine on plasma levels of desipramine [letter]
27. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction
28. The debrisoquin hydroxylation test predicts steady‐state plasma levels of desipramine [letter]
29. Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquin in healthy subjects and in human liver microsomes
30. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects
31. Drug interaction between sertraline and desipramine or imipramine [abstr]
32. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine
33. Inhibition of hepatic P‐450 isoenzymes by selective serotonin reuptake inhibitors: invitro and invivo findings and their implications for patient care
34. Haloperidol plasma levels and clinical response: a therapeutic window relationship
35. Metabolism and bioactivation of clozapine by human liver in vitro
36. Metabolism of haloperidol: clinical implications and unanswered questions
37. Elevation of plasma concentrations of haloperidol after the addition of fluoxetine
38. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects
39. Fluoxetine‐induced akathisia: clinical and theoretical implications
40. Interaction of metoprolol and fluoxetine [letter]
41. Noninvasive tests of CYP3A enzymes
42. Oxidation of the antihistaminic drug terfenadine in human liver microsomes: role of cytochrome P‐450 3A(4) in N‐dealkylation and C‐hydroxylation
43. Terfenadine‐ketoconazole interaction: pharmacokinetic and electrocardiographic consequences
44. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin
45. Astemizole: a review of its pharmacodynamic properties and therapeutic efficacy
46. Torsades de pointes associated with astemizole (Hismanal) therapy [letter]
47. Long QT syndrome during high‐dose cisapride
48. Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men
49. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants
50. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine
51. Fluoxetine impairs clearance of alprazolam but not of clonazepam
52. A pharmacokinetic evaluation of the combined administration of triazolam and fluoxetine
53. A potentially hazardous interaction between erythromycin and midazolam
54. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole and itraconazole
55. Coadministration of nefazodone (NEF) and benzodiazepines I: pharmacokinetic assessment [abstract]
56. Probable terfenadine‐fluoxetine‐associated cardiac toxicity [letter]
57. Fluoxetine‐associated potentiation of calcium‐channel blockers
58. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine
59. Loratadine administered concomitantly with erythromycin: pharmacokinetic and electrocardiographic evaluations
60. Human liver carbamazepine metabolism: role of CYP3A4 and CYP2C8 in 10,11‐epoxide formation
61. Interaction between carbamazepine and fluvoxamine
62. Increased carbamazepine plasma concentrations after fluoxetine coadministration
63. Carbamazepine coadministration with fluoxetine or fluvoxamine
64. Caffeine metabolism in a healthy Spanish population: N‐acetylator phenotype and oxidation pathways
65. The use of caffeine for enzyme assays: a critical appraisal
66. Caffeine metabolism by human hepatic cytochromes P450: contribution of 1A2, 2E1 and 3A isoforms
67. Fluvoxamine is a potent inhibitor of cytochrome P4501A2
68. Toxic interaction between fluvoxamine and sustained release theophylline in an 11‐year‐old boy
69. Biochemistry and molecular biology of the human CYP2C subfamily
70. Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin
71. The role of serotonin in thrombogenesis
72. Fluoxetine inhibition of phenytoin metabolism
73. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S‐mephenytoin, but not debrisoquin, hydroxylation phenotype
74. Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers